Need an investment idea? Check out Popular Stocks and S2O Stock Screener.

Market Price

118.24 

-2.15 -1.8%

as of May 05 '16 16:00

52 Week Range:

71.63 131.84


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis that is used for the treatment of multiple myeloma; bazedoxifene, which is used for the treatment of postmenopausal osteoporosis; Nexterone, a Captisol-enabled formulation of amiodarone; Noxafil-IV, a Captisol-enabled formulation of posaconazole for IV use; Exemptia for autoimmune diseases; and Vivitra for breast cancer. The company’s partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, kidney disease, and others. Its internal development program comprise products for the treatment of Type 2 diabetes mellitus, blood disorders, anti-coagulant, pain, depression, allergy, sun damage, restless leg/parkinson's, cognitive disorders, oncology, and inflammation. The company is also involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated has alliances, licenses, and other business relationships with various pharmaceutical companies, including Novartis, Amgen, Inc, Merck & Co., Inc., Pfizer Inc., Celgene, Gilead, Janssen, Baxter International, Inc., and Eli Lilly and Company. The company was founded in 1987 and is headquartered in La Jolla, California.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

Item Name Dec '05 Dec '06 Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15
Equity (BVPS) -8.90
-15.15
1.85
-0.66
0.19
-0.25
0.12
1.31
2.19
2.27
14.65
growth rate 0.0% 100.0% -100.0% 100.0% -100.0% 100.0% 991.7% 67.2% 3.7% 545.4%
Earnings BIT 36.34
-174.27
-53.46
-97.52
-9.87
-15.40
-2.95
-3.87
9.21
growth rate -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0%
Avg.PE -17.00
-15.70
-20.90
-3.20
-34.50
-15.00
22.99
-118.50
121.95
98.34
8.25
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -100.0% 100.0% -19.4% -91.6%
ROA -11.25
-9.91
112.83
-56.92
-1.24
-9.54
10.28
-0.47
10.93
6.63
64.98
growth rate 0.0% 100.0% -100.0% 0.0% 0.0% 100.0% -100.0% 100.0% -39.3% 880.1%
ROE 36.70
-142.60
997.71
-1,046.50
-69.00
-365.80
536.00
-3.00
30.01
31.67
155.61
growth rate -100.0% 100.0% -100.0% 0.0% 0.0% 100.0% -100.0% 100.0% 5.5% 391.4%
ROIC 561.34
-803.41
35.22
3.76
20.13
8.45
69.87
growth rate -100.0% 100.0% -89.3% 435.4% -58.0% 726.9%
Cur. Ratio 0.57
1.38
2.16
1.33
1.31
1.11
0.74
0.67
0.86
8.13
10.35
growth rate 142.1% 56.5% -38.4% -1.5% -15.3% -33.3% -9.5% 28.4% 845.4% 27.3%
Quick Ratio 0.46
1.07
1.85
1.31
1.22
1.08
0.67
0.60
0.78
7.94
10.17
growth rate 132.6% 72.9% -29.2% -6.9% -11.5% -38.0% -10.5% 30.0% 918.0% 28.1%
Leverage 11.92
5.95
37.88
14.15
3.94
2.11
9.80
1.75
growth rate -50.1% 152.3% -38.9% -72.2% -46.5% 364.5% -82.1%
Balance Sheet Dec '05 Dec '06 Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15
Acct.Receivable 0.00
0.60
1.00
12.54
8.92
6.55
12.63
10.95
growth rate 66.7% 1,154.4% -28.9% -26.5% 92.9% -13.3%
Acct.Payable 16.12
12.40
10.86
12.56
9.48
growth rate -23.1% -12.4% 15.7% -24.6%
Cur.Assets 93.90
68.20
37.00
32.23
23.82
24.88
185.16
215.57
growth rate -27.4% -45.8% -12.9% -26.1% 4.4% 644.2% 16.4%
Total Assets 171.40
141.80
75.60
120.58
104.26
104.71
258.03
533.93
growth rate -17.3% -46.7% 59.5% -13.5% 0.4% 146.4% 106.9%
Cash 28.80
16.00
3.30
7.04
12.38
11.64
160.20
97.43
growth rate -44.4% -79.4% 113.4% 75.8% -6.0% 1,276.4% -39.2%
Inventory 0.00
0.00
0.00
1.30
1.70
1.39
0.27
1.63
growth rate 30.4% -18.0% -80.7% 507.1%
Cur.Liabilities 70.60
52.20
33.50
43.64
35.44
28.94
22.78
20.84
growth rate -26.1% -35.8% 30.3% -18.8% -18.3% -21.3% -8.5%
Liabilities 181.80
138.10
80.40
104.05
77.78
55.10
231.71
229.54
growth rate -24.0% -41.8% 29.4% -25.3% -29.2% 320.5% -0.9%
LT Debt 170.18
2.16
0.63
49.70
36.30
0.00
28.65
19.41
3.07
196.84
205.37
growth rate -98.7% -71.0% 7,826.6% -27.0% -100.0% -32.3% -84.2% 6,309.7% 4.3%
Equity -98.07
39.70
41.46
1.98
3.70
3.50
8.19
26.49
49.61
26.32
304.39
growth rate 100.0% 4.4% -95.2% 86.9% -5.4% 133.9% 223.6% 87.3% -47.0% 1,056.6%
Common Shares 12.00
13.00
16.00
16.00
19.00
20.00
20.00
20.00
21.00
21.00
21.00
growth rate 8.3% 23.1% 0.0% 18.8% 5.3% 0.0% 0.0% 5.0% 0.0% 0.0%
Cash Flow Statement Dec '05 Dec '06 Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15
Capital Expenditures 35.60
1.78
0.44
0.40
0.40
0.70
0.08
0.60
0.38
0.01
0.09
growth rate -95.0% -75.3% -9.1% 0.0% 75.0% -88.9% 662.8% -36.6% -98.4% 1,450.0%
Cash Dividends 0.00
0.00
252.74
0.00
0.00
0.00
0.00
0.00
growth rate -100.0%
Cash From OA 8.37
-138.52
-97.73
-20.63
-33.80
-27.07
-1.17
0.16
20.69
20.57
41.73
growth rate -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% 12,750.9% -0.6% 102.9%
FCF per Share -0.86
-3.44
-6.00
-1.33
-1.82
-1.38
-0.42
-0.02
0.34
1.03
1.58
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% 202.9% 53.4%
Sale Purchase of Stock 0.00
6.42
3.13
-51.76
8.36
growth rate 100.0% -51.3% -100.0% 100.0%
FCF -27.00
-140.00
-98.00
-21.00
-34.00
-27.00
-1.00
-0.40
17.00
20.00
38.00
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% 17.7% 90.0%
Income Statement Dec '05 Dec '06 Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15
Sales 10.22
3.98
12.89
27.30
38.90
23.50
30.04
31.39
48.97
64.54
71.91
growth rate -61.1% 223.9% 111.8% 42.5% -39.6% 27.8% 4.5% 56.0% 31.8% 11.4%
Op.Income -97.30
-10.00
-29.30
9.71
-2.67
8.83
12.02
257.31
growth rate 0.0% 0.0% 100.0% -100.0% 100.0% 36.1% 2,039.9%
IBT -97.50
-9.90
-15.40
-3.56
-3.87
9.21
11.30
35.33
growth rate 0.0% 0.0% 0.0% 0.0% 100.0% 22.8% 212.6%
Net Income -98.10
-1.90
-10.40
9.71
-2.67
8.83
12.02
257.31
growth rate 0.0% 0.0% 100.0% -100.0% 100.0% 36.1% 2,039.9%
EPS -2.94
-2.34
17.22
-6.18
-0.12
-0.53
0.52
-0.03
0.55
0.56
12.12
growth rate 0.0% 100.0% -100.0% 0.0% 0.0% 100.0% -100.0% 100.0% 1.8% 2,064.3%
Gross Profit 10.22
3.98
12.89
27.30
38.90
23.50
25.13
27.79
43.24
55.40
66.11
growth rate -61.1% 223.9% 111.8% 42.5% -39.6% 6.9% 10.6% 55.6% 28.1% 19.3%
R&D 30.80
39.90
22.10
10.29
10.79
9.27
12.12
13.38
growth rate 29.6% -44.6% -53.4% 4.9% -14.1% 30.7% 10.4%

Quarterly Statements

Item Name Dec '14 Mar '15 Jun '15 Sep '15 Dec '15
Balance Sheet
Acct.Receivable 12.96
7.51
11.08
18.58
10.95
growth rate -42.0% 47.5% 67.7% -41.1%
Acct.Payable 12.82
11.96
8.34
7.30
9.48
growth rate -6.7% -30.3% -12.5% 29.9%
Cur.Assets 185.16
191.71
196.73
210.32
215.57
growth rate 3.5% 2.6% 6.9% 2.5%
Total Assets 258.03
263.22
304.76
521.70
533.93
growth rate 2.0% 15.8% 71.2% 2.3%
Cash 160.20
165.77
108.24
94.37
97.43
growth rate 3.5% -34.7% -12.8% 3.2%
Inventory 0.27
2.82
0.80
1.63
growth rate 948.7% -71.6% 42.7%
Cur.Liabilities 22.78
18.16
17.95
16.25
20.84
growth rate -20.3% -1.2% -9.5% 28.2%
Liabilities 231.71
228.08
235.71
229.52
229.54
growth rate -1.6% 3.4% -2.6% 0.0%
LT Debt 196.84
198.80
200.80
202.95
205.37
growth rate 1.0% 1.0% 1.1% 1.2%
Equity 26.32
35.15
69.05
292.18
304.39
growth rate 33.6% 96.5% 323.1% 4.2%
Common Shares
growth rate
Cash Flow Statement Dec '14 Mar '15 Jun '15 Sep '15 Dec '15
Capital Expenditures 0.01
0.01
0.02
0.07
growth rate 66.7% 70.0% 97.0%
Cash Dividends
growth rate
Cash From OA 10.25
7.58
10.05
10.44
13.67
growth rate -26.0% 32.6% 3.9% 30.9%
Sale Purchase of Stock -28.99
0.78
4.65
1.46
1.47
growth rate 100.0% 495.3% -68.6% 0.7%
FCF 10.24
7.57
10.03
13.60
growth rate -26.1% 32.5% 16.5%
Income Statement Dec '14 Mar '15 Jun '15 Sep '15 Dec '15
Sales 23.00
14.60
18.42
17.70
21.19
growth rate -36.5% 26.1% -3.9% 19.7%
Op.Income 7.06
0.75
22.69
222.37
11.49
growth rate -89.3% 2,909.8% 879.9% -94.8%
IBT 7.01
-0.07
22.29
7.28
5.83
growth rate -100.0% 100.0% -67.3% -20.0%
Net Income 7.06
0.75
22.69
222.37
11.49
growth rate -89.3% 2,909.8% 879.9% -94.8%
EPS
growth rate
Gross Profit 19.00
13.53
15.82
16.45
20.31
growth rate -28.8% 16.9% 4.0% 23.4%
R&D 3.28
3.96
4.01
2.54
2.87
growth rate 20.8% 1.2% -36.7% 13.1%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

A+ (92.15)

YOY Growth Grade:

D (44.14)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 8.46 9.76 20.14
EPS / Growth 41.6% 12.12 46.0%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 50.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 40.0% 45.9% 62.5%
Future PE 8.46 16.25 51.22
Future EPS 350.58 528.28 1,558.97
Value Price
MOS %
733.12
520.0%
2,121.54
1,694.3%
19,737.82
16,593.0%
MOS Price 366.56 1,060.77 9,868.91
IRT 3.95 3.68 3.17

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

Access denied

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE.